ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Dr. Finkelstein Discusses the Safety Profile of Radium-223

Steven E. Finkelstein, MD
Published: Tuesday, Sep 03, 2013
For High-Definition, Click
Steven E. Finkelstein, MD, National Director of Translational Research, 21st Century Oncology, discusses the safety profile of radium-223 (Xofigo) to treat patients with bone metastases from castration-resistant prostate cancer (CRPC).

Finkelstein says the most common adverse reactions the patients experienced after receiving radium-223 were nausea, diarrhea, vomiting, and peripheral edema. Grade 3 and 4 adverse events were reported in 57% of radium-223-treated patients while 63% of placebo-treated patients reported such reactions, Finkelstein says, proving that radium-223 is a tolerable agent.

Anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia were the most common hematologic laboratory abnormalities in radium-223-treated patients, Finkelstein says.

As radium-223 is a radionucleotide, Finkelstein says, radiation oncologists and nuclear medicine physicians both possess appropriate training to use the agent.

Finkelstein says that radium-223 was created in a specific way to become a practical option for community oncologists.

As the ALSYMPCA trial demonstrated a tolerable toxicity profile for radium-223, Finkelstein says, patients will be able to receive chemotherapy if radium-223 is ineffective.



Slider Left
Slider Right
For High-Definition, Click
Steven E. Finkelstein, MD, National Director of Translational Research, 21st Century Oncology, discusses the safety profile of radium-223 (Xofigo) to treat patients with bone metastases from castration-resistant prostate cancer (CRPC).

Finkelstein says the most common adverse reactions the patients experienced after receiving radium-223 were nausea, diarrhea, vomiting, and peripheral edema. Grade 3 and 4 adverse events were reported in 57% of radium-223-treated patients while 63% of placebo-treated patients reported such reactions, Finkelstein says, proving that radium-223 is a tolerable agent.

Anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia were the most common hematologic laboratory abnormalities in radium-223-treated patients, Finkelstein says.

As radium-223 is a radionucleotide, Finkelstein says, radiation oncologists and nuclear medicine physicians both possess appropriate training to use the agent.

Finkelstein says that radium-223 was created in a specific way to become a practical option for community oncologists.

As the ALSYMPCA trial demonstrated a tolerable toxicity profile for radium-223, Finkelstein says, patients will be able to receive chemotherapy if radium-223 is ineffective.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x